Results 1 to 10 of about 475,313 (268)

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

Annals of Internal Medicine, 2020
Background: The new coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS–CoV-2), has caused more than 210 000 deaths worldwide. However, little is known about the causes of death and the virus's pathologic features.
D. Wichmann, J. Sperhake, M. Lütgehetmann, S. Steurer, C. Edler, A. Heinemann, F. Heinrich, H. Mushumba, I. Kniep, A. Schröder, Christoph Burdelski, G. de Heer, A. Nierhaus, D. Frings, S. Pfefferle, H. Becker, Hanns Bredereke-Wiedling, A. de Weerth, H. Paschen, Sara Sheikhzadeh-Eggers, A. Stang, S. Schmiedel, C. Bokemeyer, M. Addo, M. Aepfelbacher, K. Püschel, S. Kluge   +26 more
semanticscholar   +3 more sources

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

British medical journal, 2021
Objective To assess rates of cardiovascular and haemostatic events in the first 28 days after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S in Denmark and Norway and to compare them with rates observed in the general populations.
A. Pottegård, L. Lund, Ø. Karlstad, J. Dahl, M. Andersen, J. Hallas, Ø. Lidegaard, G. Tapia, H. Gulseth, P. L. Ruiz, S. Watle, A. Mikkelsen, L. Pedersen, H. Sørensen, R. Thomsen, A. Hviid   +15 more
semanticscholar   +1 more source

Epidemiology and prevention of venous thromboembolism

Nature Reviews Cardiology, 2022
In this Review, Lutsey and Zakai describe the epidemiology of venous thromboembolism, including incidence, risk factors and outcomes; summarize opportunities for primordial, primary and secondary prevention; and highlight the importance of reducing ...
P. Lutsey, N. Zakai
semanticscholar   +1 more source

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Journal of Thrombosis and Haemostasis, 2020
Three months ago, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) broke out in Wuhan, China, and spread rapidly around the world. Severe novel coronavirus pneumonia (NCP) patients have abnormal blood coagulation function, but their venous ...
Songping Cui, Shuo Chen, Xiunan Li, Shi Liu, Feng Wang   +4 more
semanticscholar   +1 more source

Incidence of venous thromboembolism in hospitalized patients with COVID‐19

Journal of Thrombosis and Haemostasis, 2020
Coronavirus disease 2019 (COVID‐19) can lead to systemic coagulation activation and thrombotic complications.
S. Middeldorp, M. Coppens, T. V. van Haaps, M. Foppen, A. Vlaar, M. Müller, C. Bouman, L. Beenen, R. Kootte, J. Heijmans, L. Smits, P. Bonta, N. van Es   +12 more
semanticscholar   +1 more source

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Journal of Clinical Oncology, 2020
PURPOSE To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs ...
N. Key, A. Khorana, N. Kuderer, Kari Bohlke, Agnes Y. Y. Lee, J. Arcelus, S. Wong, E. Balaban, C. Flowers, C. Francis, L. Gates, A. Kakkar, M. Levine, H. Liebman, M. Tempero, G. Lyman, A. Falanga   +16 more
semanticscholar   +1 more source

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

New England Journal of Medicine, 2020
BACKGROUND Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer.
G. Agnelli, C. Becattini, G. Meyer, A. Muñoz, M. Huisman, J. Connors, A. Cohen, R. Bauersachs, B. Brenner, A. Torbicki, M. R. Sueiro, C. Lambert, G. Gussoni, M. Campanini, A. Fontanella, G. Vescovo, M. Verso   +16 more
semanticscholar   +1 more source

COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms

Thorax, 2021
Thrombotic events that frequently occur in COVID-19 are predominantly venous thromboemboli (VTE) and are associated with increasing disease severity and worse clinical outcomes.
Joan Loo, D. Spittle, M. Newnham
semanticscholar   +1 more source

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Blood Advances, 2020
BACKGROUND Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States annually. OBJECTIVE These
T. Ortel, I. Neumann, W. Ageno, R. Beyth, N. Clark, A. Cuker, B. Hutten, M. Jaff, Veena Manja, S. Schulman, Caitlin Thurston, S. Vedantham, P. Verhamme, D. Witt, Ivan D. Florez, A. Izcovich, R. Nieuwlaat, S. Ross, Holger J. Schünemann, W. Wiercioch, Yuan Zhang, Yuqing Zhang   +21 more
semanticscholar   +1 more source

Abelacimab for Prevention of Venous Thromboembolism.

New England Journal of Medicine, 2021
BACKGROUND The role of factor XI in the pathogenesis of postoperative venous thromboembolism is uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation.
P. Verhamme, B. Yi, A. Segers, J. Salter, D. Bloomfield, H. Büller, G. Raskob, J. Weitz   +7 more
semanticscholar   +1 more source